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Abstract Thisreviewexplores thehealth and socialburdenof someofthemainrespiratorydiseases (asthma, chronic
obstructive pulmonary disease, cryptogenic fibrosing alveolitis, cystic fibrosis, lung cancer, mesothelioma, obstructive
sleep apnoea andtuberculosis) in order to increase awarenessofthese diseases andhighlight areaswhereimprovements
in care are required.The overall impact of respiratory diseases in the U.K. in terms of prevalence, mortality, morbidity,
and economic costs, with particular reference to secondary care has been considered and comparisonsmade with the
restof Europewhere data are available.Respiratorydiseases areresponsible for a significantproportion of seriousmor-
bidity and premature death among the population of the U.K. and they will continue to present a growing challenge;
special support is needed to tackle this burden.r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
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Respiratory diseases are responsible for a signi¢cant
proportion of serious morbidity and premature death
among the population of the U.K. They are one of the
most frequentcauses of hospital admission, primary care
consultation and death in this country (1). The most re-
cent data available show that respiratory diseases ac-
count for 6.5% of hospital admissions (2,3) and 24% of all
deaths in the U.K. (4). In addition, 30% of the population
have consulted their GP at least once because of disor-
ders of the respiratory system. GP consultation rates
for respiratory diseases are over three times as high as
for diseases of the circulatory or digestive systems (5).
Furthermore, in 1996, a national audit of acute medical
admissions carried out by the Research Unit of TheReceived 23 April 2002, accepted in revised form 29 April 2002.
Correspondence should be addressed to: Prof.Fan Chung,National
Heart & Lung Institute, Imperial College School of Medicine,
Dovehouse Street, London SW3 6LY,U.K.Fax: +44 (0)20 73518126;
E-mail: f.chung@ic.ac.ukRoyal College of Physicians found that, of the 3385 ran-
domly selected case notes for hospital in-patients re-
viewed at 42 district general hospitals, 27% were due to
respiratory disorders (6). Respiratory was the second
largest diagnostic category, after cardiac, which ac-
counted for 29% of emergency admissions.
In terms of indirect costs, nearly 15% of the
working population in the U.K. report work-limiting
health problems from respiratory diseases (2,3).
Indeed, in1995/96,18.3 million working days were lost in
the U.K. due to asthma alone (7). Despite these high
¢gures, there is a general lack of awareness and
knowledge about the extentof theburden of respiratory
diseases in the U.K. and how the U.K. compares with
other European countries. Moreover, it is commonly
perceived that respiratory diseases are under control;
however, some conditions, such as chronic obstructive
pulmonary disease (COPD), are actually increasing in
prevalence.
This review, therefore, explores the health and social
burden of some of the main respiratory diseases of
964 RESPIRATORYMEDICINEconcern in the U.K. today: asthma, COPD, cryptogenic
¢brosing alveolitis (CFA), cystic ¢brosis, lung cancer,me-
sothelioma, obstructive sleep apnoea (OSA) and
tuberculosis (TB). We consider the overall burden of
these diseases in theU.K. in terms of prevalence,mortal-
ity, morbidity, and economic costs, with particular refer-
ence to secondary care. Comparisons with the rest of
Europe are made where data are available. In compiling
these data, we have identi¢ed areaswhere there are fail-
ings and unmet needs, and areas where important com-
parative data are lacking. From this, it is apparent that
there is a need to set national standards of care.We have
also attempted to predict future trends and develop-
ments in the burden and treatment of particular respira-
torydiseases and their consequences for secondarycare.
In comparing the current status of pulmonary disease in
the U.K. with that of European countries, we aim to in-
crease awareness of the burden of respiratory diseases
and highlight areas where improvements in care would
bene¢t the health of the nation.
ASTHMA
Asthma is a common and chronic in£ammatory condi-
tion a¡ecting the airways.More than 3 million people in
theU.K., includingmore than1.3million children, are cur-
rentlydiagnosed as having asthma (8), and at least 20% of
children aged 2^15 years are now a¡ected by it (4). Re-
cently, the prevalence of the disease in the U.K. has risen
signi¢cantly in both children and adults (9^11). The in-
creasewas paralleled by an increase in atopy andwas not
due to heightened awareness of asthma.General practiceFIG. 1. Twelve-monthprevalence of self-reportedasthma symptomsrconsultation rates for asthma increasedmore than 2-fold
between 1981 and 1991, with rates for children aged 0^4
years increasing 7-fold, while consultations for upper re-
spiratory tract infections remained constant (12).
In terms of incapacity, asthma is a signi¢cant cause of
short-term absence from work in the U.K., with 1.9% of
all certi¢eddays of incapacity, and the amountof sickness
bene¢tpaid out is rising.TheAsthma Insights and Reality
in Europe (AIRE) study, a telephone survey in seven Eur-
opean countries carried out in spring 1999 (13), found
38% of children and 16% of adults in the U.K. had lost
school/workdays due to their asthma in the past year.
Several international studies indicate that asthma is
more prevalent in the U.K. than inmany other European
countries. In the European Community Respiratory
Health Survey (ECRHS) study (14), the age ^ sex-standar-
dised prevalence of asthma symptoms (e.g., nocturnal
wakening) among adults was generally higher in the
U.K., Ireland and other Northern European countries
compared with Southern Europe (Fig.1) (1). The Interna-
tional Study of Asthma and Allergies in Childhood
(ISAAC) (15) found thatof the 56 participating countries,
the U.K. had the highest current prevalence of self-re-
ported asthma symptoms among children aged 13^14
years, higher thanother comparable European countries
such asGermany (19th) and France (20th).Figure 2 shows
the prevalence of asthma symptoms in European coun-
tries participating in ISAAC.The AIRE study found that
the household prevalence of diagnosed asthmawas high-
est in theU.K. (15.2%) and lowest in Germany (2.5%) (13).
Deaths from asthma rose in the early1980s, peaking in
1988 at just over 2000 per year, with the increase more
noticeable in the older age groups (16). Since then asthmaesults ofthe European Community RespiratoryHealth Survey (14).
FIG. 2. Twelve-month prevalence of self-reported asthma
symptomsinthe Europeancountries (15).
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counted for 1521 deaths in the U.K. (4). This decrease in
mortality is likely to be due to improved care and treat-
ment relating to the development and dissemination of
asthma management guidelines, although further im-
provements couldbemade throughbetter care and edu-
cation. Increased funding, as observed in Finland, to
provide structured care, training and greater expertise
leads to a fall in mortality (18). In the U.K. however, de-
spite the apparent fall in mortality, the prevalence of
asthma symptoms is still high.Themajor burden of asth-
ma lieswith chronic on-going symptoms andhospital ad-
missions rather thanmortality.
The majority of asthma deaths occur in those aged
over 45 years (16), with around 40% of deaths occurring
in individuals aged 75 years and over. Asthma mortality
in the U.K. is higher than in other European countries. In
1996, the age-standardised mortality rates from asthma
in the U.K. were 105 per 100 000, compared with 44 in
France and 43 in Germany (4).
Asthma exerts a considerable persistent burden on
the U.K.’s National Health Service (NHS). In the AIRE
study, 27% of asthma patients in the U.K. had required
acute health-care services over the preceding year (13).
Hospital admissions due to asthma have increased in all
age groups over the last 30 years, most dramatically in
the 0^4 year age group (19). In1995/96, the estimated to-
tal cost for hospital in-patients with asthma in the U.K.
was d50 million; the estimated total cost to the NHS
was d672 million (8). At present, around 10% of asthma
health-care costs occur in secondary care and some of
these costs canbe attributed to suboptimalprimarycare
management (8). Comparison with European countries
indicates that the hospital discharge rate for asthma in
the period 1990^1994 was higher in England and Wales(approximately 200 discharges per 100 000) than in all
other EU countries except Finland (20).
CHRONICOBSTRUCTIVE
PULMONARYDISEASE
COPD is a chronic air£owobstruction causedby emphy-
sema and peripheral airway obstruction from chronic
bronchitis, which primarily a¡ectsmen andwomen aged
over 45 years (21).The major cause of COPD is tobacco
smoking, which accounts for 80^90% of cases, and this is
re£ected in its epidemiology (21).Currently,COPDranks
as the ¢fth most common cause of mortality and mor-
bidity worldwide, being responsible for an estimated 2.9
million adultdeathsper year (22,23). In theU.K., the pre-
valence of physician-diagnosed COPD in 1997, as deter-
mined from the General Practice Research database,
was 1.36% in women and 1.65% in men; these rates are
the lowest estimates of the burden of COPDF‘the tip
of the iceberg’ (23). In 1995, the prevalence of COPD, as
reported by the O⁄ce for National Statistics, was1% in
the general population, 2% inmen aged 45^65 years, and
7% in men aged over 75 years (24). Although the preva-
lence of COPD inmen in theU.K. seems to have reached
a plateau in the mid-1990s, prevalence in women of all
ages is still increasing (23). International estimates of
COPD prevalence are unavailable (21), but a model esti-
mating COPD prevalence on the basis of smoking rates
places the U.K. calculated a prevalence in those aged
445 of 2.96 million, ahead of Germany (2.66 million),
Italy (2.64 million), France (2.63 million) and Spain (1.52
million) (25).
By 2020, it is estimated that COPD will be the third
most common cause of death in the world (26). In 1998,
there were 26 630 deaths due to COPD in England and
Wales, however this is probably an underestimate, as
COPD is a co-morbid condition with many other dis-
eases that are attributed instead as primary cause of
death (1).Mortality rates for COPD vary widely in di¡er-
ent European countries, with the U.K. having one of the
highest rates (Fig. 3) (27).
In 1995/96, the total estimated annual costs of COPD
to theNHS approached d500million, with almost half of
these costs occurring in secondary care; emergency ad-
missions accounted for 78% of secondary care costs
(d174 million) (28). Hospital admissions in1998/99 due to
COPD accounted for an estimated 952495 in-patient
bed-days compared with 201240 in-patient bed-days for
asthma (Table 1) (29). A typical general hospital in the
U.K., serving a population of about 250 000, will admit
680 patients with COPD per year, of whom 90 will have
type 2 (hypercapnic) respiratory failureresulting froman
acute exacerbation of COPD (30). In primary care, the
number of GP consultations for COPD was four times
greater than that for angina (5).
FIG. 3. Age-adjustedmortalityrates for COPD for people aged 35^74 years in the U.K. and Europe (27).
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ciatedwith increasedmortality and a higher need for in-
tubation (30).Non-invasiveventilation (NIV) is of proven
bene¢t in these patients in terms of length of hospitalTABLE 1. Hospital admissions for COPDand asthma (29)
1998^1999 1999^2000a
COPD Asthma COPD Asthma
Numberof
hospital admissions
92 535 61358 94534 57 344
Meanlength
of stay
10.4 days 3.3 days 10.2 days 3.3 days
Numberof in-patient
bed-days
952494 201240 953393 186 008
aProvisional data.
COPD: chronic obstructive pulmonarydisease.
TABLE 2. Thenumberof respiratory intensive care units in1998,U
Contry No. of RICUs No. of beds
U.K. 10 450
Denmark 2 10^15
France 16 170
Germany 15 70
Greece 2 15
Holland 6 50
Italy 22 143
Spain 1 8
Switzerland 4 20
RICU: respiratory intensive care unit.stay, mortality and intubation rates (30^33). A typical
U.K. hospital will admit 90 patients per year with acido-
sis, of which 72 (80%)will requireNIV (30). A recent sur-
vey found that NIV was available in less than half of U.K.
hospitals and that this de¢cit was largely deemed due to
lack of resources (34). The availability of respiratory in-
tensive care units is also less than ideal, with availability
in the U.K. and throughout Europe standing at around
one-tenth of that recommended (Table 2) (35).
The availability of home treatment for COPD patients
is also important for improving quality of life and redu-
cing health-care costs. However, major di¡erences exist
between the countries of Europe with regard to home
treatment services. An example of this can be seen in
France, which has a similar sized population as the U.K.
In France, home mechanical ventilation is mainly orga-
nised through the public system, using a national net-
work of 33 Regional Associations for home care of
chronic respiratory insu⁄ciency, which are federated.K. vs.Europe (35)
Type ofmonitoring system Nurse: patient ratio
Non-invasive F
Non-invasive 1:2^1:3
Mainly invasive 1:2
Invasive and ?non-invasive 1:3^1:4
Non-invasive 1:3
Invasive 1:2
Non-invasive 1:3^1:4
Invasive and ?non-invasive 1:2
Invasive and ?non-invasive 1:2
FIG. 4. Mortality rates for cryptogenic ¢brosing alveolitis in
England and Wales, Scotland,Canada, Australia, New Zealand,
Germanyand the United States (42).
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Association for Chronic Respiratory Insu⁄ciency (AN-
TADIR). At the end of 1991, 23 623 patients with COPD
were being treated at home for respiratory failure (36).
Of these,14173 patients receivedlong-termoxygen ther-
apy, with the remainder on home ventilation (tracheost-
omy, nasal mask ventilation or continuous positive
airway pressure [CPAP]). Such structured, organised
care is non-existent in the U.K. and is highly desirable.
CRYPTOGENICFIBROSING
ALVEOLITIS
CFA is themost common of the interstitial lung diseases
(37); however, the aetiology of CFA is unknown and cur-
rently there are no e¡ective treatments. Characteristi-
cally,CFA is a disease of latemiddle age and occurs twice
as frequently inmales as females.The reason for this sex
di¡erence is unclear; no clear genetic factors have been
described. Although a familial form of the disease is re-
cognised, it is extremely rare, occurring in 1.34 per mil-
lion of the U.K. population (38). Patients with familial
CFA areyounger atdiagnosis, but are otherwise indistin-
guishable from non-familial patients.
Data derived from theU.K.General Practice Research
Database and the 4th Morbidity Survey in General Prac-
tice (39) suggest that the12-month prevalence of CFA in
theU.K. is1.5^1.8 per10 000 personyears.Given that the
median survival of newly diagnosed cases of CFA is 3
years (40), this suggests an incidence of CFA in the U.K.
of 0.5 per10 000 person years.Data comparing the pre-
valence of CFA in the U.K. with that in other countries
are lacking.
Annualmortality from CFA in the U.K. rose from 336
in 1979 (when the disease received a speci¢c Interna-
tional Classi¢cation of Diseases code) to 702 in1988 (41).
A study ofmortality due to CFA in seven countries (Eng-
land andWales [combined], Scotland,Canada, Australia,
NewZealand,Germany, and the U.S.A.) identi¢ed a con-
tinuingrise from1979 to1992, except in theU.S.A. where
the mortality rate fell (42). CFA mortality rates were
highest in England and Wales and Scotland, and lowest
in Germany and the U.S.A. (Fig. 4) (42): mortality in the
U.K. from CFA in the early1990s was more than10-fold
higher than inGermany and theU.S.A..Clearly,more re-
search is needed into CFA as there are very few data
considering themorbidity, mortality and economic costs
associatedwith this condition.
CYSTICFIBROSIS
Cystic ¢brosis is the most common autosomal recessive
fatal disease among Caucasians.Themajor cause of mor-
bidity and mortality is chronic progressive lung disease,
and secondary health care is focused on improving thehealth and quality of life of people with cystic ¢brosis.
The incidence of cystic ¢brosis in the U.K. has remained
relatively constant over the past three decades (43). Ap-
proximately 300 infants with cystic ¢brosis are born
each year (Table 3), giving an incidence of 1/2415 live
births (44).Births of cystic ¢brosis babies in theU.K. cur-
rently outnumber deaths by around160 per year, so the
prevalence of cystic ¢brosis is increasing (44).On the ba-
sis of these data, therewere an estimated 7750 cystic ¢-
brosis patients in theU.K. in 2000.The incidence of cystic
¢brosis varies across Europe from 1/4200 live births in
Denmark to1/2000 in Belgium (Table 3).
The survival of individuals with cystic ¢brosis has
been improving steadily in the U.K. and elsewhere.
The infant mortality rate for cystic ¢brosis is nowo20/
1000 per year and early childhoodmortality iso5/1000
per year; more than one-third of cystic ¢brosis patients
are now adults (44). The estimated mortality rate
between the ages of 20 and 30 years is 50/1000 and
adult survival has shown no evidence of recent improve-
ment (43).
International cystic ¢brosismortality rates show simi-
lar trends. National mortality data from 10 countries in
North America, Australasia and Europe, including the
U.K., reveal that the median age of survival increased
from 8 to 21 years between 1974 and 1994, though there
were signi¢cant di¡erences in survival between coun-
tries (45). Between1980 and1994, the proportion of pa-
tients dying from cystic ¢brosis at an age above the
international median was 54% in the U.S.A. compared
TABLE 3. Incidence of cystic ¢brosis in U.K. and Europe
Country Totalpopn
(000)
Total births/year
(000)
CF births/year CF incidence (1:) Numberof people
with CF (adults)
U.K. 57 700 802 300 2700 5630 (2100)
Austria 8970 98 43 2800 550 (80)
Belgium 10100 120 50 2000 1500 (254)
Bulgaria 8430 84 34 2500 600 (20)
Czech Republic 10 000 110 45 2500 370 (800)
Denmark 5100 70 16 4200 350 (151)
France 58 027 708 240 3000 6000 (1500)
Germany 81500 800 250 3500 3470 (1090)
Ireland 3500 50 30 1200 (250)
Russia 144 000 1300 420 4000 1612 (153)
Spain 39791 340 100 4000 2300 (600)
Switzerland 6969 84 40 800 (150)
CF: cystic ¢brosis.
TABLE 4. Resources for cystic ¢brosis in the U.K. and Europe (1995 data)
Country No. of centres (with adultclinics) Median survival (years) No. of patients (adults)
U.K. 39 (22) 25/26 5630 (2100)
Belgium 8 (4) 22 1500 (254)
Bulgaria 1 (0) 10 600 (20)
Czech Republic 6 (1) 21.7 370 (80)
Denmark 2 (2) 80%440 350 (151)
France 60 (8) 40a 6000 (1500)
Russia 15 (?) 15 1612 (153)
Spain 26 (26) 24 2300 (600)
Switzerland 9 (2) 25 800 (150)
aEstimated survival for a child born after1995.
968 RESPIRATORYMEDICINEwith 32% in Scotland. The prospects for survival in
England andWales were better than in Scotland but still
inferior to the U.S.A., Ireland and Sweden.
Attendance at specialist cystic ¢brosis clinics in the
U.K. confers bene¢ts in respect of both lung function
andnutritional status (45). A reportby the Royal College
of Physicians in1991recommended that eachNHSregion
should have at least one cystic ¢brosis centre.Within the
U.K., there are now 39 centres, 22 of which provide a
service for adults (Table 4).Resources in terms of the ra-
tio of specialistclinics to patients in theU.K. appear tobe
at least as good as in Belgium and Denmark but slightly
inferior to those in France, Spain and Switzerland
(Table 4).
Aggressive treatment of chronic lung infections in a
specialist cystic ¢brosis centre in Denmark has achieved
a drop in the mortality rate of chronically infected pa-
tients from 10^20% before 1976 to 1^2% in 1984^1985
(46). Age-speci¢c mortality data for 1989^1993 suggest
cystic ¢brosis patients in Denmark have an 83.3% (CI
80.1^86.6%) probability of surviving 40 years after initialdiagnosis, a value far in excess of publisheddata for other
European countries.
LUNGCANCER
Lung cancer is the most common form of cancer in the
U.K. and, with more than 34 000 deaths per year, the
most common cause of cancer mortality (4). The vast
majority (90%) of primary lung cancers are caused by ci-
garette smoking.There are two main types of lung can-
cerFsmall-cell lung cancer and non-small-cell lung
cancer, the latter accounting for around 75% of lung can-
cer cases.
In 1997 there were 21000 newly diagnosed cases of
lung cancer in men in England and Wales, and 12 300
cases in women (47). The incidence of lung cancer in
men has shown a long-term decline since the 1980s as a
result of the decrease in smoking. In contrast, female
lung cancer in theU.K. is expected to rise, with numbers
predicted to nearly equal those in men by 2015, unless
FIG. 5. Age-standardised international incidence of lungcancer in (a) men and (b) women (47).
BURDENOFRESPIRATORYDISEASE 969there is amarkedchange in smokingbehaviour (48).Lung
cancer is also the leading form of cancer inmostwestern
European and North American countries, but rates are
comparatively low in India and in several African and
South American countries (Fig. 5). The very high rates
of lung cancer in industrialised countries re£ect the sub-
stantial increases in the consumption of cigarettes by
men since the First World War and in women since the
Second.
In 1998, U.K. mortality rates in males were 19 per
100 000 in the 35^54 age group and 254 per 100 000 in
the 55^74 age group (Fig. 6). Mortality rates from lung
cancer have halved in the male population since the
1960s (49), this is due mainly to the widespread pro-
longed cessation in smoking rather than improvements
in treatment outcome. In contrast, mortality rates from
lung cancer in U.K. females have £uctuated in parallel
with changes in the number of women smokers. Death
from lung cancer in the 35^54 age group peaked during
the late1970s at16 per100 000 andhas since decreased to
12 per 100 000. In the 55^74 age group, mortality rate
peaked in the early 1990s at 126 per 100 000 and de-
creased to120 per100 000 by1998 (Fig. 6) (49).Mortality rates attributed to lung cancer vary across
Europe according to the smoking habits of the popula-
tion,whileHungaryhas thehighestreportedlung cancer
mortality in the world (50). The increasing incidence of
lung cancer in Europeanwomen is of particular concern:
Denmark, which has particularly high rates of female
smoking, now has the highest rate of female mortality
from lung cancer in Europe (51).
The duration of survival of European patients with
lung cancer has been assessed in the European Union-
funded EUROCARE II study (52). This collaborative in-
vestigation involving17 European countries assessed the
survival of 173 448 patients diagnosed with lung cancer
between1985 and1989.The study revealed a large varia-
tion in the treatment of lung cancer and its outcome
both within di¡erent regions of the U.K. and between
theU.K. and other European countries (52,53).One-year
survival rates varied from 24 to 40%, the highest being in
Finland,France and TheNetherlands, the lowestbeing in
England, Poland and Scotland. Relative 5-year survival
rates varied from 6% in England to 14% in Switzerland.
The 1- and 5-year survival rates for men and women by
age group (15^44, 55^64 and 75+) are presented in
FIG. 6. Lungcancermortalityrates inmen andwomeninthe U.K. from1950 to1997 (49).
TABLE 5. One- and ¢ve-year relative survival of adult patientswith lungcancer (1985^1989) bycountry and age (52)
Age (years) 1-year survivalrate (%) 5-year survivalrate (%)
15^44 55^64 75+ 15^44 55^64 75+
England 36 27 15 17 9 3
Scotland 31 28 14 14 8 2
Denmark 36 29 15 13 8 2
France 48 42 30 20 14 6
Germany 47 36 22 24 12 5
Italy 39 36 22 16 12 5
Poland 47 32 15 16 8 3
Slovakia 40 35 28 19 12 17
Spain 36 34 23 18 13 10
Switzerland 50 47 27 24 13 5
Netherlands 42 45 28 19 15 7
970 RESPIRATORYMEDICINETable 5.The EUROCARE study has now been extended
to includepatients diagnosedup to1992 (EUROCARE III),
but these data are not yet available.
MESOTHELIOMA
Mesothelioma is a malignant tumour of the pleura that is
extremely rare in populations that have not been ex-
posed to asbestos. In the U.K., asbestos exposure cur-
rently accounts for nearly 700 new cases of the disease
annually (54).On the basis of asbestos exposure and lag
time, it is forecast that the incidence of mesothelioma in
the U.K. will gradually rise, reaching a peak in 2020^25,
before declining gradually thereafter (55,56). A pre-
dicted 1750 men in the U.K. will develop mesothelioma
each year between 2015 and 2019. Current and future
incidence of mesothelioma in other European countries
is similar to that in the U.K. (56) (Fig. 7) although onereport suggests that this is higher in France (57). At
present, care of patients with mesothelioma is solely
palliative though some chemotherapeutic regimens are
looking promising in U.K. trials.
OBSTRUCTIVESLEEPAPNOEA
OSA, caused by complete or partial pharyngeal collapse
during sleep, is an important cause of excessive daytime
sleepiness and has associated signi¢cant adverse conse-
quences for a¡ected individuals and others (58).OSA is
an underdiagnosed medical problem in the U.K. (59),
where its prevalence, as elsewhere in Europe, is 1^2% in
men over the age of 35 (60); OSA is more prevalent in
men thanwomen (approximately 2:1) (58,60).
Although there are no speci¢c mortality data avail-
able, the social and health economic burdens of OSA
are high and underestimated: OSA is associated with
FIG. 7. Observed (to1989) andpredicted (1990^2029) annualnumbers of pleural cancerdeaths in six European countries (56).
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creased quality of life, a 5- to 10-fold increased risk of
road accidents (61) and increased use of medical re-
sources (59).OSA may cause daytime hypertension (62)
and reduce longevity (58).
The status of secondary care for OSA in the U.K. was
assessed byThe Royal College of Physicians in 1993 (62).
AlthoughU.K. facilities for themanagementofOSAhave
since improved, they still lag behind other European
countries where there are more adequate resources for
sleep investigation and treatment. Most centres in the
U.K. have major funding problems and educational and
research resources are inadequate (60). A postal survey
in 1995^1996 revealed ¢nancial problems in 34/43 cen-
tres, inadequate diagnostic facilities in 23 centres, inade-
quate sta⁄ng at 25 centres and insu⁄cient treatment
facilities in 26 centres.
The most e¡ective treatment of symptomatic OSA is
bynasal continuouspositive airwaypressure (CPAP) (62).
Although CPAP is cost e¡ective (an average gain of 5.5QALYs at d2000/QALY), less than one in 20 suitable pa-
tients in the U.K. receive the treatment. One hundred
and eighty thousand individuals could bene¢t in the
U.K.Faround 900 per average U.K. health district of
250 000 (60). There are widespread di¡erences in the
provision of CPAP within the U.K. which should be ad-
dressed urgently.
TUBERCULOSIS
TB is a serious infectious disease with a high worldwide
incidence. The incidence of TB in western countries fell
from the time of the First World War until the mid-
1990s when this fall levelled o¡. Since then, the incidence
of TB has started to rise again,with cases of TB clustered
in areas of social deprivation. A recent report indicates
that in the incidence of tuberculosis, England and Wales
increased by 22% during the 1990s (4). In the U.K. there
were 6161cases of TB reported in1995, rising to 6240 and
972 RESPIRATORYMEDICINE6355 in 1996 and 1997, respectively (64). This upward
trend continued in 1998. However, TB noti¢cation rates
are still very small at 10.6, 10.7 and 10.8 per 100 000 for
1995,1996 and1997, respectively, so it is hard to comment
on overall increases. In comparison to many European
countries, the prevalence of TB in the U.K. is relatively
low, with only Iceland, Malta,The Netherlands, Norway
and Sweden having a lower prevalence.
The increase in prevalence of TB is particularly
marked in Eastern Europe, where it is at least partly a
result of the rise in antibiotic-resistant strains of Myco-
bacterium tuberculosis. The problem of multidrug-resis-
tant (MDR) strains (combined resistance to isoniazid
and rifampicin) varies across Europe. Fifty cases of MDR
TBwerereported in theU.K. in1998, representing 0.75%
of all noti¢cations (22). A further 188 patients (2.8%)
were infectedwith strainsresistant to isoniazid or rifam-
picin. MDR strains are still relatively infrequent in most
other countries inWestern Europe, but are an increasing
problem in Eastern Europe; in Estonia13% of strains iso-
lated in1997 were MDR strains (64).However, increased
travel from areas of high prevalence may lead to the
spread ofMDRTB.Recentreports from France and Swit-
zerland indicate that most TB patients with drug resis-
tance are foreign immigrants (65,66).
Mortality rates forTB inWestern Europevary, but are
generally low. Mortality is highest in Portugal (2.8 per
100 000 population) and lowest inThe Netherlands (0.3
per100 000) (67).
Treatment of MDR TB is very expensive: the cost of
managing a case of MDRTBwas found to be in excess of
d60 000 compared with just over d6000 for drug-sensi-
tiveTB (68). AsTB care is high on the U.K.Government’s
list of priorities, measures for controlling TB should be
maintained and enhanced.
DISCUSSION
These data highlight the substantial burden respiratory
diseases impose on the U.K. population and health-care
services, and the current gross under-provision of re-
sources. Respiratory diseases are major causes of mor-
tality and morbidity and take up a signi¢cant amount of
health-care resources. For many respiratory diseases,
prevalence and mortality rates are higher in the U.K.
than in other European countries, and provision of ser-
vices for diagnosis and treatment is both inadequate and
inferior to that of our European neighbours.While there
have been improvements in service provisionFfor ex-
ample, the number of chest physicians in England,Wales
and Northern Ireland has increased from 365 in 1993 to
482 in1999Frespiratorymedicine resources still lag be-
hind those of other areas such as cardiology (with 581
consultants) and geriatric medicine (with 803 consul-
tants) (69). Moreover, the proportion of funding fromcharitable organisations that goes to respiratory-based
projects is far less than other specialities such as cardiol-
ogy or oncology.
The burden of respiratory disease, and of COPD, lung
cancer and TB in particular, is greater amongst socially
deprived groups (5).Targeting these groups and improv-
ing access to health care is high on theU.K.Government’s
agenda. Smoking cessation is a particularly important
factor in preventing of two of the most prevalent re-
spiratory diseases, COPD and lung cancer.While there
has been a decline in the number of adults who smoke
since the 1970s, the rate of decline has slowed in recent
years andmay, indeed have reversed (70).The U.K. Gov-
ernment has set out a comprehensive agenda to reduce
smoking within the U.K. population in the White Paper
Smoking Kills, which is backed by a d100 million invest-
ment in treatment and education.Targets have been set
to reduce smoking among adults from 28 to 24%, among
children from13 to 9% and among pregnantwomen from
23 to 15%, by 2010. However, the impact of these mea-
sures on smoking-induced diseasewill not be felt for an-
other 20^30 years.
Asthma is a very common condition in theU.K. and its
prevalence is increasing. It imposes a substantial ¢nancial
burden on both primary and secondary health-care ser-
vices. Although death rates have fallen recently (prob-
ably as a result of improved management), about 1500
people still die from asthma each year and the majority
of these deaths are preventable (71). Mortality remains
higher in theU.K. than in Europe.Treatment non-compli-
ance andundertreatment are signi¢cant issues in asthma
management (72).More specialist asthma care and train-
ing and support of health professionals are likely to be
important factors in improving care (73,74).
COPD places a huge burden on health-care resources
in the U.K. because of its high prevalence, the signi¢cant
disability it causes and the generally advanced state of
disease at the time of initial presentation. A considerable
proportion of COPD treatment takes place in secondary
care as a result of delayed diagnosis and inappropriate
management (particularly smoking cessation) in primary
care (75).Comparisons with other countries are di⁄cult
to make, as de¢nitions of the condition vary through
time and country (25), but U.K. mortality appears to be
higher than in Europe. This review has highlighted the
need for increasedprovision ofrespiratory intensive care
beds and improved availabilityofNIV forCOPDpatients.
The lackof resources and training that appears to under-
lie the poor availability of NIV (34) is an area deserving
attention.
Although dramatic improvements have been made in
the management of cystic ¢brosis, with many patients
nowreaching adulthood, the survival of cystic ¢brosis pa-
tients in the U.K. is inferior to that elsewhere in Europe
and the U.S.A..This is probably due to a combination of
variations in socio-economic status, genotypic variation,
BURDENOFRESPIRATORYDISEASE 973distribution and virulence of pathogenic organisms and
access to appropriate and optimal health-care facilities
(45). The experience of physicians in Denmark shows
that further improvements in outcome could be
achieved with improved therapeutic approaches in spe-
cialist clinics, particularly for adults. Greater manage-
ment of the condition with multidisciplinary care teams
might as well bring improvements (76). Most of the 150
patients with cystic ¢brosis who die each year in the
U.K.wouldhavebene¢ted from a heart^lung transplant;
the main limiting factor here is the shortage of donors,
and this ismore apparent for ethnic minorities.
The poor survival of U.K. lung cancer patients relative
to our European neighbours is another area of obvious
concern.The most likely explanation for the di¡erences
is variation in access to specialised care (52).The number
of specialist consultants in theU.K. is lower than inmost
other European countries, and many patients with lung
cancer will never see an oncologist (77).
In this review,wehave also highlighted the undertreat-
ment of OSA, which is a greatly underestimated condi-
tion in terms of the numbers a¡ected and its impact on
their lives. Driver and Vehicle Licensing Agency (DVLA)
regulations in the U.K. require drivers to cease driving if
they are excessively sleepy from any cause.Group1 (pri-
vate license) driverswith a diagnosis of OSA should noti-
fy the DVLAbutmay continue to drive provided they do
not have excessive awake-time sleepiness, whereas
Group 2 drivers (drivers of public service and heavy
goods vehicles) should not drive until the DVLA has re-
ceived written con¢rmation from a specialist that their
condition is adequately treated (61).Greater recognition
and diagnosis of the condition, andprovision of CPAP are
urgently needed if these regulations are to be met and
the quality of life of su¡erers and their families is to be
improved.
The burden of respiratory disease seems set to in-
crease. Incidences of CFA, which is not a rare disease,
andmesotheliomawill rise, and therefore, research into
new treatments is needed for both these conditions.The
ageing population coupled with the cumulative e¡ect of
female smoking is likely to increase the burden of COPD
in the U.K.: adequate resources need to be made avail-
able to ensure good patient care. In addition, smoking
cessation rates, particularly in younger women, need to
be improved if we are to in£uence COPD and lung can-
cer trends. Although the prevalence of TB in the U.K. is
relatively low, the spread of MDRTB and changes in the
epidemiology of the disease are likely to have signi¢cant
implications for treatment in theU.K.Treatment facilities
will need to be targeted towards vulnerable populations
such asHIV-positive individuals, thehomeless and the so-
cially deprived: a retrospective study of TB in Birming-
ham has suggested that TB will be entirely a problem of
ethnic minorities by around 2010 in the U.K. (78). More
expensive treatment approaches, such as directly ob-served treatment, short course (DOTS), may be needed
to prevent the emergence of drug resistance (79). New
developments in the prevention and treatment of re-
spiratory disease, such as gene therapy for cystic ¢brosis
(80,81) andphosphodiesterase inhibitors, cytokine block-
ers and new drug delivery systems for COPD (82), will
also impinge on treatment strategies andwill need to be
incorporated into future secondary care policies.
The status given to respiratory diseases in national
secondary health-care policies will a¡ect outcome. The
U.K.Government is currently establishing National Ser-
vice Frameworks (NSFs) which will set national stan-
dards and provide a systematic and multidisciplinary
approach to speci¢c health-care areas. Cancer was in-
cluded into the NSF in1995 (83).This exposed problems
with standards of care, and highlighted the need for in-
creased funding and resources.The report thenwent to
describe the direction in which cancer services in Eng-
land andWales should be developed.
As we have shown in this review, respiratory diseases
meet several of the NSF inclusion criteria: they are an
important cause of mortality andmorbidity; they are an
area of public concern; and real improvements could be
made by greater provision of resources, specialist care,
training and appropriate facilities to bring the standard
of care and outcomeup to that seen in neighbouring Eur-
opean countries. Inclusion of respiratory disease into the
NSF would ensure that patients receive a better and
more consistent service in both primary and secondary
cares and could have a signi¢cant impact on future re-
source allocations, which are currently limited. How-
ever, this review has also pinpointed areas where U.K.
and comparative European data are lacking.There is still
a considerable need for up-to-date statistics and valid in-
ternational comparisons based on standardised study
methods, statistics and diagnostic criteria. Such data
would provide valuable information on optimal diagnos-
tic and therapeutic strategies and resource provision,
and would strengthen the case for inclusion of respira-
tory disease in the NSF.
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